NASDAQ · NRSNW
NeuroSense Therapeutics Ltd.
Healthcare · Biotechnology
$0.01
Down-$0.03 (-63.64%)
Updated Oct 10, 2026, 8:45 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 8.85M
- P/E ratio
- -2.6
- Dividend yield
- 0.00%
- 52-week range
- $0.01 – $0.27
- Volume
- 9.15K
- Avg. volume
- 6.95K
Price performance · NRSNW
NRSNW price history
1M range · 13 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
NRSNW closed at $0.01 after 13 trading sessions, down 72.04% for the selected period.
- Last close
- $0.01
- Period change
- -72.04%
- Period low
- $0.01
- Period high
- $0.09
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.0396 | $0.0396 | $0.0144 | $0.0144 | 9.15K |
| Oct 5, 2026 | $0.0602 | $0.0602 | $0.0396 | $0.0396 | 7.84K |
| Oct 2, 2026 | $0.045 | $0.045 | $0.04 | $0.04 | 2.27K |
| Sep 29, 2026 | $0.0403 | $0.045 | $0.0403 | $0.045 | 516 |
| Sep 25, 2026 | $0.0401 | $0.0401 | $0.0401 | $0.0401 | 1.11K |
| Sep 24, 2026 | $0.09 | $0.09 | $0.08 | $0.09 | 3.71K |
| Sep 23, 2026 | $0.063 | $0.07 | $0.063 | $0.0699 | 5.48K |
| Sep 22, 2026 | $0.04 | $0.0443 | $0.0398 | $0.0443 | 6.55K |
| Sep 21, 2026 | $0.04 | $0.045 | $0.04 | $0.04 | 1.31K |
| Sep 18, 2026 | $0.045 | $0.045 | $0.045 | $0.045 | 5.09K |
| Sep 17, 2026 | $0.0445 | $0.049 | $0.0445 | $0.049 | 746 |
| Sep 16, 2026 | $0.0513 | $0.0513 | $0.0456 | $0.0456 | 6.02K |
| Sep 14, 2026 | $0.0515 | $0.0515 | $0.0515 | $0.0515 | 206 |
Latest NRSNW news
The latest Smart Investors Daily articles mentioning NRSNW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NRSNW research
Overview
Company profile and research snapshot.
Company profile
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
